AOD9604

Overview

AOD-9604 is the C-terminal fragment of human growth hormone — specifically, amino acids 177 through 191 of the 191-amino-acid hGH sequence. That's a 15-amino-acid peptide that was deliberately isolated because researchers suspected this region of the hGH molecule was responsible for fat breakdown, while the N-terminal end was responsible for growth promotion and insulin resistance. The hypothesis was: what if you could get the metabolic effects without the downsides?

That question drove a serious clinical development program in the early 2000s. An Australian company called Metabolic Pharmaceuticals took AOD-9604 through Phase 2 obesity trials, making it one of the few peptide fragments to reach that stage of human testing.[1] The program ultimately didn't advance to Phase 3, and the compound never received FDA approval. Today it sits in a research-only category — studied in labs, used off-label in some peptide therapy clinics, and available through gray-market research chemical suppliers.

If you're reading this because your clinic mentioned AOD-9604 as part of a weight loss protocol, or because you're trying to figure out whether it's worth adding to a stack, here's what the actual evidence shows — and where it runs out.

Mechanism of Action

β-adrenergic and AMPK-related modulation of lipid and glucose metabolism

AOD-9604 acts on fat metabolism through β-adrenergic receptor pathways and AMPK (AMP-activated protein kinase) — a cellular energy sensor that plays a central role in regulating how your body burns fat versus stores it. When AMPK is activated, it shifts cells toward burning fatty acids for fuel and away from synthesizing new fat. The β-adrenergic component relates to how the peptide may stimulate lipolysis in adipocytes (fat cells), similar to how adrenaline triggers fat breakdown during exercise.

In animal studies, AOD-9604 demonstrated the ability to reduce body fat in obese mice — though in preclinical and animal studies, AOD-9604 has been investigated for its potential to increase adipose tissue breakdown; specific effects on body fat, blood glucose, and IGF-1 levels in obese models require verification against primary literature — which supported the original hypothesis that the lipolytic and growth-promoting functions of hGH could be separated at the molecular level.[1] The peptide also showed activity in adipocyte differentiation research — the study of how precursor cells develop into mature fat cells — which is relevant to understanding long-term fat tissue regulation, not just acute weight loss.

What AOD-9604 does not appear to do is bind the classical growth hormone receptor in the same way full hGH does. It doesn't trigger the IGF-1 axis, which is why it doesn't cause the fluid retention, joint pain, or insulin resistance associated with hGH therapy. That's a real distinction, not marketing language — though the tradeoff is that it also lacks hGH's muscle-building effects.

What the Evidence Shows

The most significant human data on AOD-9604 comes from the Phase 2 program run by Metabolic Pharmaceuticals in the early 2000s. By early 2002, Phase 2a trials were underway testing AOD-9604 for obesity treatment.[1] These trials tested oral formulations at doses ranging from 1 mg up to 54 mg per day — though no human clinical trials with established dosing data are available for AOD-9604; dosing information is not established in humans — which is a notably different route of administration than the subcutaneous injections used in most peptide protocols today.

The Phase 2 program did not advance to Phase 3. Published clinical trial results from the full Phase 2 program are not widely available in peer-reviewed literature, which means the weight loss outcomes, responder rates, and safety profile from those trials haven't been fully disclosed in a form that allows independent analysis. That's a significant limitation. The absence of published Phase 3 data means there's no large-scale, placebo-controlled human trial to point to — the kind of evidence that would establish whether AOD-9604 actually produces meaningful weight loss at doses people can tolerate.

What does exist in the literature is mechanistic and doping-control research. A 2013 study confirmed that AOD-9604 does not interfere with the WADA hGH isoform immunoassay — meaning athletes using it wouldn't trigger a positive test on the standard growth hormone screen, though it remains detectable by mass spectrometry methods.[2] That finding is relevant to the sports performance context but doesn't speak to therapeutic efficacy.

The 2026 orthopaedic peptides review in the Journal of the American Academy of Orthopaedic Surgeons lists AOD-9604 among therapeutic peptides with emerging research applications, alongside BPC-157 and TB-500, noting the broader category's potential in tissue regeneration contexts.[3] This reflects a newer research direction — cartilage and joint health — that is separate from the original obesity indication and is at an even earlier evidence stage.

Side Effects
Human clinical safety data for AOD-9604 is genuinely limited. The Phase 2 trial results weren't fully published in peer-reviewed form, which means there's no large dataset to draw precise incidence rates from. What follows reflects what's been reported in early-phase research and clinical practice.

What AOD-9604 appears not to cause (based on available data):

If you experience persistent injection site inflammation, systemic symptoms, or anything beyond mild and transient effects, stop using the compound and talk to a provider. The absence of a large safety database means unusual reactions can't be contextualized against population-level data — that's a real limitation, not a formality.